<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02542007</url>
  </required_header>
  <id_info>
    <org_study_id>RECOVERY Combo 2015-01</org_study_id>
    <nct_id>NCT02542007</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of the Combo Bio-engineered Sirolimus-eluting Stent Versus the Nano Polymer-free Sirolimus-eluting Stent in the Treatment of Patients With de Novo Stenotic Lesions</brief_title>
  <acronym>RECOVERY</acronym>
  <official_title>RECOVERY: A Prospective, Multi-center, Randomized Controlled Trial Evaluating the Safety and Efficacy of the Combo Bio-engineered Sirolimus-eluting Stent Versus the Nano Polymer-free Sirolimus-eluting Stent in the Treatment of Patients With de Novo Stenotic Lesions of Native Coronary Artery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OrbusNeich</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CCRF Inc., Beijing, China</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>OrbusNeich Medical (Shenzhen), Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>OrbusNeich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety, efficacy and deliverability of the Combo bio-engineered&#xD;
      sirolimus-eluting stent versus the Nano polymer-free sirolimus- eluting stents in the&#xD;
      treatment of patients with de novo stenotic lesions of native coronary artery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multi-center, open-label, non-inferiority, randomized controlled trial&#xD;
      which plans to enroll 436 subjects. All subjects enrolled will be randomly assigned to the&#xD;
      test group (n=218) and the control group (n=218). Subjects in the test group and the control&#xD;
      group will receive Combo stents and Nano stents respectively.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">June 10, 2021</completion_date>
  <primary_completion_date type="Actual">May 27, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In-segment late lumen loss (LLL)</measure>
    <time_frame>9 months post-procedure</time_frame>
    <description>In-segment late lumen loss (LLL) refers to within the margins of the stent and 5 mm proximal and 5 mm distal to the stent.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device-oriented target lesion failure (TLF)</measure>
    <time_frame>30 days, 6 months, 12 months and annually up to 5 years</time_frame>
    <description>The device-oriented target lesion failure (TLF) defined as a composite of cardiac death, target vessel myocardial infarction (MI), and ischemia-driven target lesion revascularization (i-TLR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-oriented composite endpoint</measure>
    <time_frame>30 days, 6 months, 12 months and annually up to 5 years</time_frame>
    <description>The patient-oriented composite endpoint includes all-cause death, all MIs, or any revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent late lumen loss (LLL)</measure>
    <time_frame>9 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent and In-segment binary restenosis (BR)</measure>
    <time_frame>9 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent and In-segment minimal lumen diameter (MLD)</measure>
    <time_frame>9 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Definite and probable stent thrombosis (ST)</measure>
    <time_frame>acute (0-24 hours), sub-acute (24 Hours to 30 Days), late (30 Days to 1 year) and very late (1 year to 5 years) period per Academic Research Consortium (ARC) definition criteria</time_frame>
    <description>Definite and probable stent thrombosis (ST) in acute, sub-acute, late and very late period per Academic Research Consortium (ARC) definition criteria</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">440</enrollment>
  <condition>Coronary Arteriosclerosis</condition>
  <arm_group>
    <arm_group_label>OrbusNeich Combo stent™</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nano Polymer-free sirolimus-eluting stent system</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The Nano polymer-free sirolimus-eluting stent produced by LePu medical.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OrbusNeich Combo stent™</intervention_name>
    <description>The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.</description>
    <arm_group_label>OrbusNeich Combo stent™</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>sirolimus-eluting stent system</intervention_name>
    <arm_group_label>Nano Polymer-free sirolimus-eluting stent system</arm_group_label>
    <other_name>Nano Polymer-free sirolimus-eluting stent system</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with clinical evidence of asymptomatic or symptomatic ischemic heart disease,&#xD;
             stable or unstable angina, old myocardial infarction;&#xD;
&#xD;
          -  De novo lesions of native coronary arteries (lesions number ≤2);&#xD;
&#xD;
          -  Target lesion located in one or two different vessels. The number of target lesions in&#xD;
             one vessel shall be no more than one;&#xD;
&#xD;
          -  Target vessel diameter between 2.5 and 4.0 mm by visual estimation. Target lesion&#xD;
             length ≤ 32mm by visual estimation, which can be covered by one Combo stent with&#xD;
             length 38mm or one Nano stent with length 36mm. It is suggested that the selected&#xD;
             stent size should cover at least 2 mm (by visual estimation) of normal tissue on each&#xD;
             side of the lesion;&#xD;
&#xD;
          -  Target lesion diameter stenosis ≥ 70% by visual estimation;&#xD;
&#xD;
          -  Each target lesion is permitted to implant only one stent at most, except bailout&#xD;
             stent;&#xD;
&#xD;
          -  Patients is eligible for PCI and is an acceptable candidate for CABG;&#xD;
&#xD;
          -  Patients with left ventricular ejection fraction (LVEF) ≥40%;&#xD;
&#xD;
          -  Patients who can understand the nature of the study, agree to participate and accept&#xD;
             angiographic and clinical follow-up, and have provided written informed consent;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with acute myocardial infarction (AMI) within one week;&#xD;
&#xD;
          -  Chronic total occlusion lesion (TIMI 0 flow), Left main disease, Ostial lesion, and/or&#xD;
             triple-vessel lesion that might require treatment, bifurcation lesions with a side&#xD;
             branch diameter &gt;2.5mm or graft lesions;&#xD;
&#xD;
          -  Heavily calcified or tortuous lesions which cannot be successfully pre-dilated, and&#xD;
             lesions which are not suitable for stent delivery and deployment;&#xD;
&#xD;
          -  In-stent restenosis;&#xD;
&#xD;
          -  Thrombotic lesion;&#xD;
&#xD;
          -  Patients who had received any other stent in the past six months;&#xD;
&#xD;
          -  Patients with acute or chronic renal dysfunction (defined as creatinine greater than&#xD;
             2.0 mg/dl);&#xD;
&#xD;
          -  Patients with cardiogenic shock, acute infection, known bleeding or coagulation&#xD;
             disorder, or with a history of active gastrointestinal bleeding, ulcer, cerebral&#xD;
             hemorrhage or subarachnoid hemorrhage and stroke within 6 months;&#xD;
&#xD;
          -  Patients who are allergic to aspirin, clopidogrel, ticagrelor, ticlopidine, heparin,&#xD;
             contrast agent, sirolimus, stainless steel , polymer, or with contraindication to&#xD;
             aspirin or clopidogrel or ticagrelor;&#xD;
&#xD;
          -  Patients who had previously received murine therapeutic antibodies and exhibited&#xD;
             sensitization through the production of HAMA;&#xD;
&#xD;
          -  Patients with a life expectancy less than 1year;&#xD;
&#xD;
          -  Patients who had participated in another investigational drug or device trial that has&#xD;
             not completed the primary endpoint;&#xD;
&#xD;
          -  Patient who has received any organ transplant or is on a waiting list for any organ&#xD;
             transplant;&#xD;
&#xD;
          -  Patient is in the opinion of the investigator, unable to comply with the requirements&#xD;
             of the study protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tao Ling, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of the Fourth Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xu Bo, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Secondary Affiliated Hospital of Harbin University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Daqing General Oilfield Hospital</name>
      <address>
        <city>Daqing</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanjing First Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Japan Union Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The people Hospital of Liaoning Province</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Secondary Affiliated Hospital of Shanxi Medical University</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kunming General Hospital of Chengdu Military region</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Chao Yang Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Military General Hospital of Beijing PLA</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bethune International Peace Hospital</name>
      <address>
        <city>Shijiazhuang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjing Chest Hospital</name>
      <address>
        <city>Tianjing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TEDA International Cardiovascular Hospital</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University General Hospital</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of the Fourth Military Medical University</name>
      <address>
        <city>Xi'an, Shanxi</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 1, 2015</study_first_submitted>
  <study_first_submitted_qc>September 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2015</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>intracoronary stent</keyword>
  <keyword>drug eluting stent</keyword>
  <keyword>sirolimus</keyword>
  <keyword>endothelial progenitor cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arteriosclerosis</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

